Camp4 Therapeutics Corp. Stock Price, News & Analysis

CAMP (Nasdaq: CAMP) reported Q3 2025 results and corporate updates on Nov 6, 2025. Key items include a private placement initial closing of $50M (up to $100M total) that management says extends runway into 2027, and cash and marketable securities of $75.3M as of Sept 30, 2025 (up from $39.1M on June 30, 2025).

Clinical progress: initiated GLP toxicology studies for CMP-002 to support a planned Phase 1/2 filing with potential trial start as early as H2 2026; completed MAD analysis for CMP-001 showing favorable safety and PK and received a Netherlands CTA to start a Phase 1b in OTC heterozygotes. Q3 operating items: R&D $9.4M, G&A $4.6M, net loss $15.1M.

CAMP4 Therapeutics (Nasdaq: CAMP) has initiated GLP toxicology studies for CMP-SYNGAP-01, their lead product candidate targeting SYNGAP1-related disorders. The company aims to submit a clinical trial application that could lead to a Phase 1/2 clinical trial beginning in H2 2026.

Preclinical studies have shown promising results, with CMP-SYNGAP-01 successfully restoring SYNGAP1 protein levels in mouse models and increasing protein levels in relevant brain regions of non-human primates. SYNGAP1-related disorders, affecting 0.5% to 1.0% of intellectual disability cases, currently lack FDA-approved disease-modifying treatments.

CAMP4 Therapeutics (NASDAQ: CAMP) has secured an oversubscribed private placement of up to $100 million to advance its SYNGAP1 program. The financing includes $50 million in upfront proceeds and potential for an additional $50 million tied to achieving specific milestones, including regulatory clearance for a Phase 1/2 clinical trial.

The initial financing comprises 26,681,053 shares of common stock at $1.53 per share, with additional shares for directors and employees at $1.65, and pre-funded warrants. The placement is led by Coastlands Capital, with participation from investors including Janus Henderson, Balyasny Asset Management, and Vivo Capital.

Alongside this financing, Doug Williams, Ph.D., has been appointed as Board Chair, and Daniel Tardiff, Ph.D., will become Chief Scientific Officer effective October 1, 2025. The company plans to initiate its Phase 1/2 clinical trial for SYNGAP1-related disorders as early as 2H 2026.

CAMP4 Therapeutics (NASDAQ:CAMP) reported Q2 2025 financial results and corporate updates, highlighting progress in its RNA-targeting therapeutics pipeline. The company presented positive translational data for its SYNGAP1-related disorders program at the ASGCT Annual Meeting, demonstrating efficacy in mouse models and increased protein levels in non-human primates.

Key developments include plans to initiate GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025, with potential Phase 1/2 trial initiation in H2 2026. The company completed dosing in the third MAD cohort for CMP-CPS-001, with comprehensive data expected in Q4 2025. Financial position shows $39.1 million in cash and equivalents, with Q2 R&D expenses of $10.3 million and a net loss of $12.6 million.

CAMP4 Therapeutics (NASDAQ: CAMP) presented promising data from two key programs at the 28th ASGCT Annual Meeting. For their SYNGAP1-related disorders program, CMP-SYNGAP-01 demonstrated increased SYNGAP1 protein levels in both haploinsufficient mice and non-human primates, with successful rescue of behavioral phenotypes. In mice, the treatment restored protein levels to near normal range and improved motor and spatial learning defects. In NHPs, biweekly intrathecal injections achieved a ~1.5-fold protein increase across relevant brain regions. For their Urea Cycle Disorders (UCDs) program, Phase 1 clinical trial data of CMP-CPS-001 showed favorable safety profiles in healthy volunteers. The trial enrolled 48 participants across four SAD cohorts, with no serious adverse events reported. Preclinical data showed promising results in both mice and NHPs, with up to 40% increase in ureagenesis in NHPs and dose-dependent reductions in ammonia levels in mice.

CAMP4 Therapeutics (NASDAQ: CAMP) reported Q1 2025 financial results and corporate updates. The company completed dosing in three multiple ascending dose (MAD) cohorts for CMP-CPS-001 in Urea Cycle Disorders, with safety and other data expected in Q4 2025. CAMP4 nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders, with GLP toxicology studies planned for 2025. The company submitted a CTA in Europe for a Phase 1b trial in female OTC heterozygotes. Financially, CAMP4 reported cash position of $49.3 million, R&D expenses of $10.1 million, and a net loss of $12.4 million for Q1 2025. The company will receive a $0.6 million milestone payment from Fulcrum Therapeutics under their DBA program license agreement, with potential future payments up to $70 million plus royalties.

CAMP4 Therapeutics (Nasdaq: CAMP) has announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy in New Orleans, May 13-17, 2025.

The presentations will showcase:

• Preclinical data on regulatory RNA-targeting to increase protein levels for gene expression
• Interim safety data from Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers
• Research on potential treatments for Urea Cycle Disorders and SYNGAP1-Related Disorders

Three key presentations by the company include:

• Two presentations by Dr. Dan Tardiff on targeting regulatory RNAs for treating Urea Cycle Disorders and SYNGAP1-Related Disorders
• One presentation by Dr. Yuri Maricich on the first-in-human clinical trial results of CMP-CPS-001

All presentations will take place on May 16, 2025, during the Oligonucleotide Therapeutics II session and will be available on the company's investor website.

CAMP4 Therapeutics (NASDAQ: CAMP) reported its full year 2024 financial results and provided updates on its clinical programs. The company's Phase 1 trial of CMP-CPS-001 for Urea Cycle Disorders (UCDs) is progressing, with two of four multiple ascending dose cohorts completed. Safety data is expected in Q4 2025.

Key financial highlights include:

• R&D expenses: $38.8 million (down from $40.6 million in 2023)
• G&A expenses: $14.9 million (up from $11.6 million in 2023)
• Net loss: $51.8 million (compared to $49.3 million in 2023)
• Cash position: $64.0 million (sufficient until Q2 2026)

The company nominated development candidate CMP-SYNGAP-01 for SYNGAP1-related disorders and plans to initiate GLP toxicology studies in 2025. CAMP4 also expects to begin a Phase 1b trial in female OTC heterozygotes in Q2 2025.

CAMP4 Therapeutics (NASDAQ: CAMP) has strengthened its Board of Directors with the appointments of two industry veterans: Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP. The company, focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies, aims to enhance its strategic guidance for multiple drug development programs.

Dr. Williams brings over 30 years of biopharma experience, having contributed to notable drugs like LEUKINE®, ENBREL®, and SPINRAZA®. His previous roles include President of R&D at Sana Biotechnology, EVP of R&D at Biogen, and CEO of ZymoGenetics.

Dr. Stewart, formerly Chief Medical Officer at Rhythm Pharmaceuticals and GlaxoSmithKline, has extensive clinical development experience across all trial phases and has been instrumental in launching therapies including AVANDIA® and TANZEUM®. The appointments will support CAMP4's advancement of its lead clinical program for urea cycle disorders and preclinical program for SYNGAP1-related disorders.